OHR Pharmaceutical Inc.


Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company has completed two clinical trials with squalamine lactate ophthalmic solution, 0.2%, for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained-release micro-fabricated micro-particle ocular drug delivery platform technology.